{"classes":[{"categories":[{"measurements":[{"comment":"The RDE was not established because, at the time of early study termination, dose escalation was ongoing and the dose that had evidence of the best pharmacologic activity while being below the MTD had not yet been identified.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"RDE doses were defined as pharmacodynamically active. RDE doses were not to have exceeded the MTD defined in each treatment group.","groups":[{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib QD administered as a monotherapy for up to 6 months.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set-MDS","reportingStatus":"POSTED","timeFrame":"up to Day 28","title":"Recommended Dose for Expansion (RDE)","type":"PRIMARY","unitOfMeasure":"milligrams"}